Intended for healthcare professionals

  1. Research
  2. Availability of...
  3. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
CCBYNC Open access
Research

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j4530 (Published 04 October 2017) Cite this as: BMJ 2017;359:j4530

Data supplement

Related articles

FeatureCancer drugs: high price, uncertain value
EditorialDo cancer drugs improve survival or quality of life?
CommentaryThe current model has failed
Should we accept higher p values than 0.05 for new cancer drugs?

See more

Cited by...

  • Factors affecting the feasibility of post-authorisation RCTs for conditionally authorised anticancer medicines: a multistakeholder perspective from a qualitative focus group study
  • Patients deserve better information on new drugs
  • New cancer medicines in Europe 2010-2020: comparison of medicines with or without extensions of indications
  • Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications
  • Health-related quality of life outcomes reporting associated with FDA approvals in haematology and oncology
  • Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials
  • Cost-effectiveness of the top 100 drugs by public spending in Canada, 2015-2021: a repeated cross-sectional study
  • Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health
  • Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015-2021
  • Patients need better treatments, not just more of the same
  • FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
  • Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe
  • Developing and validating a multi-criteria decision analytic tool to assess the value of cancer clinical trials
  • NICEs new methods: putting innovation first, but at what cost?
  • Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
  • The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
  • Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase
  • Mortality due to cancer treatment delay: systematic review and meta-analysis
  • Designed nanomolar small-molecule inhibitors of Ena/VASP EVH1 interaction impair invasion and extravasation of breast cancer cells
  • FDA and EMA clinical research guidelines: Assessment of trial design recommendations for pivotal psychiatric drug trials (Protocol)
  • Real-world Drug Regimens for Multiple Myeloma in a Swiss Population (2012 to 2017): cost-outcome description
  • Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare system
  • Inappropriate use of progression-free survival in cancer drug approvals
  • How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
  • EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients
  • Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
  • Flawed evidence underpins approval of new cancer drugs
  • New drugs: where did we go wrong and what can we do better?
  • Discovery of tumoricidal DNA oligonucleotides by effect-directed in-vitro evolution
  • Ab-initio discovery of tumoricidal oligonucleotides in a DNA sequencing machine
  • On fitness: how do mutations shape the biology of cancer?
  • Biomarkers for capturing disease pathology as molecular process hyperstructure
  • Premarket evaluation of medical devices: a cross-sectional analysis of clinical studies submitted to a German ethics committee
  • Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naive Prostate Cancer
  • Detection of a novel, primate-specific 'kill switch tumor suppression mechanism that may fundamentally control cancer risk in humans: an unexpected twist in the basic biology of TP53
  • Pathways to faster access to medicines
  • Choosing wisely in oncology: necessity and obstacles
  • Conflict of interest among Italian medical oncologists: a national survey
  • Healing an ailing pharmaceutical system: prescription for reform for United States and Canada
  • Removing the blindfold on medicines pricing
  • Outcomes for cancer drugs approved in Europe
  • Do cancer drugs improve survival or quality of life?
  • Cancer drugs: high price, uncertain value
Back to top